Quantitative study reveals Semaglutide decreased fat while increasing lean tissue in mice, suggesting MRI aids in metabolic health assessment.
Motivation: Fatty infiltration in skeletal muscles impairs muscle function and health. Non-invasive imaging techniques are crucial for assessing changes in muscle composition to evaluate treatments. Goal(s): This study aimed to evaluate the impact of Semaglutide, a GLP-1 agonist, on muscle fat and lean tissue composition in a mouse model of obesity induced by a high-fat diet (HFD). Approach: Using DEXA, CT, and MRI (with Dixon and magnetization transfer methods), researchers quantified muscle composition changes between Semaglutide-treated and control groups. Results: Semaglutide increased lean tissue and reduced fat in obese mice, supporting MRI as an effective tool for tracking treatment responses in muscle composition. Impact: This study highlights an advanced MRI protocol's potential for precisely assessing body composition, showing that Semaglutide improves muscle health by increasing lean tissue and reducing fat. This non-invasive imaging approach could significantly enhance monitoring in metabolic health interventions.
No takes yet. Share an insight, caveat, or question.
Aristizábal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: